Skip to main content
BIIB
NASDAQ Life Sciences

Biogen Q2 2026: Revenue Beats but EPS Plunges 85% on Apellis Integration Costs and Pipeline Milestones

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$204.29
Mkt Cap
$30.356B
52W Low
$124.556
52W High
$219.72
52W Position info
64% above low
Off High info
7.0% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

BIIB sits 64% above its 52-week low of $124.556.

Summary

Biogen reported Q2 2026 revenue of $2.74B, beating estimates, but net income fell 85% to $97.5M due to Apellis integration costs, pipeline investments, and restructuring charges. The company also announced the RayThera acquisition and the discontinuation of BIIB122.


Key Events · Earnings and Guidance · BIIB

  • Q2 Revenue Beats, Earnings Miss

    Total revenue of $2.74B (+3.4% YoY) exceeded consensus, but net income attributable to Biogen fell to $97.5M from $634.8M, with diluted EPS of $0.66 vs. $4.33 a year ago.

  • Apellis Integration Drives Restructuring

    Recognized $165.4M in restructuring charges, primarily severance and accelerated bonus payments, as part of the Apellis integration plan to realize operating synergies.

  • Pipeline Milestones and IPR&D Expense

    Acquired IPR&D, upfront and milestone expense totaled $164.0M, including a $100M payment to TJ Bio for felzartamab rights in greater China and a $45M milestone to Ionis for salanersen Phase 3 initiation.

  • RayThera Acquisition Announced

    Entered into a definitive agreement to acquire RayThera Inc. for $225M upfront plus up to $775M in milestones, adding a Phase 1 immunology asset.


Analysis · BIIB · Life Sciences

A top-line beat to $2.74B in Q2 revenue was overshadowed by a dramatic earnings collapse, as net income fell from $634.8M a year ago to just $97.5M. The decline was driven by $165M in restructuring charges tied to the Apellis integration, $164M in acquired IPR&D and milestone expenses—including $100M for felzartamab rights—and higher amortization from inventory step-ups. Beyond the numbers, the company disclosed a definitive agreement to acquire RayThera for $225M upfront, discontinued the BIIB122 Parkinson's program with Denali, and reported multiple litigation and regulatory developments. The results highlight a transformative period in which Biogen is absorbing a major acquisition while advancing its pipeline, but at a steep near-term cost to earnings.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIIB was trading at $204.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4B. The 52-week trading range was $124.56 to $219.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $249.28 info
Change: $0 (0%) info
Market Cap: $36.894B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $249.28 info
Change: -$3.72 (-1%) info
Market Cap: $36.894B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $249.28 info
Change: +$0.930 (+0.37%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info